ESMO 2023 | 2-yr RELATIVITY-047: nivolumab + relatlimab in previously untreated metastatic/unresectable melanoma

Georgina V. Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, discusses the Phase II/III RELATIVITY-047 (NCT03470922) trial, comparing nivolumab plus relatlimab to nivolumab in previously untreated metastatic or unresectable melanoma. Post hoc analyses explored efficacy based on baseline metastasis sites and time to CNS metastasis development. With a median follow-up of 25.3 months, nivolumab plus relatlimab demonstrated favorable outcomes, especially in patients without CNS metastasis at baseline. Patients with liver metastasis at baseline receiving the combination treatment have a 38% reduced risk of death compared to nivolumab alone. An advantage was also seen in patients with lung metastasis demonstrating a 28% reduction in risk of death with the treatment combination. Fewer patients on nivolumab plus relatlimab developed new CNS metastasis, suggesting potential CNS activity with the fixed-dose combination. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.